- +1 858 909 0079
- +1 858 909 0057
- [email protected]
- +1 858 909 0079
- [email protected]
Cat# | Product Name | Swiss Prot# | Size | Price (US$) | Order |
PN1322 | Recombinant Protein-Porcine reproductive and respiratory syndrome virus Major envelope glycoprotein (a.a.21 to 144) | A0SG62 | 100 µg | 1195 | |
PN1323 | Recombinant Protein-Porcine reproductive and respiratory syndrome virus GP3 envelope protein (a.a.31 to 254) | A1YZP5 | 100 µg | 1195 | |
PN1324 | Recombinant Protein-Porcine reproductive and respiratory syndrome virus GP5 envelope protein (a.a.35 to 200) | A1YZP6 | 100 µg | 1195 | |
PN1325 | Recombinant Protein-Porcine reproductive and respiratory syndrome virus GP4 envelope protein (a.a.21 to 178) | A1YZQ1 | 100 µg | 1195 | |
PN1326 | Recombinant Protein-Porcine reproductive and respiratory syndrome virus Nucleocapsid (a.a.18 to 123) | B1NE29 | 100 µg | 1195 | |
PN1327 | Recombinant Protein-Porcine reproductive and respiratory syndrome virus GP3 envelope protein (a.a.31 to 254) | A1YZP5 | 100 µg | 1195 | |
PN1328 | Recombinant Protein-Porcine reproductive and respiratory syndrome virus GP2 (a.a.41 to 256) | A1YZP9 | 100 µg | 1195 | |
PN1329 | Recombinant Protein-Porcine reproductive and respiratory syndrome virus Matrix protein (a.a.31 to 174) | B1PI37 | 100 µg | 1195 | |
PN1330 | Recombinant Protein-Porcine reproductive and respiratory syndrome virus N protein (a.a.19 to 107) | B3VI54 | 100 µg | 1195 | |
PN1331 | Recombinant Protein-Porcine reproductive and respiratory syndrome virus Major envelope glycoprotein GP5 (a.a.35 to 201) | B9TR02 | 100 µg | 1195 | |
PN1332 | Recombinant Protein-Porcine reproductive and respiratory syndrome virus Nucleocapsid protein (a.a.19 to 130) | Q1A4Y4 | 100 µg | 1195 | |
PN1333 | Recombinant Protein-Porcine reproductive and respiratory syndrome virus Glycosylated envelope protein GP5 (a.a.33 to 201) | Q8JYG0 | 100 µg | 1195 | |
PN1334 | Recombinant Protein-Porcine reproductive and respiratory syndrome virus Envelope glycoprotein (a.a.42 to 265) | Q9PZ86 | 100 µg | 1195 | |
PN1335 | Recombinant Protein-Porcine reproductive and respiratory syndrome virus Non-structural protein 3 (a.a.1579 to 1809) | Q9YN02 | 100 µg | 1195 | |
PN1336 | Recombinant Protein-Porcine reproductive and respiratory syndrome virus Non-structural protein 11 (a.a.3591 to 3813) | Q9YN02 | 100 µg | 1195 | |
PN1337 | Recombinant Protein-Porcine reproductive and respiratory syndrome virus Non-structural protein 12 (a.a.3814 to 3966) | Q9YN02 | 100 µg | 1195 | |
RPN1322 | cDNA-Porcine reproductive and respiratory syndrome virus Major envelope glycoprotein (a.a.21 to 144) | A0SG62 | 2 µg | 800 | |
RPN1323 | cDNA-Porcine reproductive and respiratory syndrome virus GP3 envelope protein (a.a.31 to 254) | A1YZP5 | 2 µg | 1115 | |
RPN1324 | cDNA-Porcine reproductive and respiratory syndrome virus GP5 envelope protein (a.a.35 to 200) | A1YZP6 | 2 µg | 825 | |
RPN1325 | cDNA-Porcine reproductive and respiratory syndrome virus GP4 envelope protein (a.a.21 to 178) | A1YZQ1 | 2 µg | 785 | |
RPN1326 | cDNA-Porcine reproductive and respiratory syndrome virus Nucleocapsid (a.a.18 to 123) | B1NE29 | 2 µg | 800 | |
RPN1327 | cDNA-Porcine reproductive and respiratory syndrome virus GP3 envelope protein (a.a.31 to 254) | A1YZP5 | 2 µg | 1115 | |
RPN1328 | cDNA-Porcine reproductive and respiratory syndrome virus GP2 (a.a.41 to 256) | A1YZP9 | 2 µg | 1075 | |
RPN1329 | cDNA-Porcine reproductive and respiratory syndrome virus Matrix protein (a.a.31 to 174) | B1PI37 | 2 µg | 715 | |
RPN1330 | cDNA-Porcine reproductive and respiratory syndrome virus N protein (a.a.19 to 107) | B3VI54 | 2 µg | 800 | |
RPN1331 | cDNA-Porcine reproductive and respiratory syndrome virus Major envelope glycoprotein GP5 (a.a.35 to 201) | B9TR02 | 2 µg | 830 | |
RPN1332 | cDNA-Porcine reproductive and respiratory syndrome virus Nucleocapsid protein (a.a.19 to 130) | Q1A4Y4 | 2 µg | 800 | |
RPN1333 | cDNA-Porcine reproductive and respiratory syndrome virus Glycosylated envelope protein GP5 (a.a.33 to 201) | Q8JYG0 | 2 µg | 840 | |
RPN1334 | cDNA-Porcine reproductive and respiratory syndrome virus Envelope glycoprotein (a.a.42 to 265) | Q9PZ86 | 2 µg | 1115 | |
RPN1335 | cDNA-Porcine reproductive and respiratory syndrome virus Non-structural protein 3 (a.a.1579 to 1809) | Q9YN02 | 2 µg | 1150 | |
RPN1336 | cDNA-Porcine reproductive and respiratory syndrome virus Non-structural protein 11 (a.a.3591 to 3813) | Q9YN02 | 2 µg | 1110 | |
RPN1337 | cDNA-Porcine reproductive and respiratory syndrome virus Non-structural protein 12 (a.a.3814 to 3966) | Q9YN02 | 2 µg | 760 |
Porcine reproductive and respiratory syndrome virus cDNA and recombinant antigen
Porcine reproductive and respiratory syndrome (PRRS) is a viral disease affecting pigs, causing reproductive failure in breeding stock and respiratory disease in growing pigs. It is caused by the PRRS virus (PRRSV), a single-stranded RNA virus. PRRSV is considered one of the most economically significant viral diseases of swine, causing significant losses to the pig industry worldwide.
Porcine reproductive and respiratory syndrome virus (PRRSV) antigen refers to the protein components of the PRRSV that can be recognized and targeted by the immune system. Recombinant PRRSV antigens can be produced in the laboratory for use in vaccines and diagnostic tests. These antigens can help stimulate the immune system to produce a protective response against PRRSV infection.
The genome of Porcine reproductive and respiratory syndrome virus (PRRSV) is a linear, positive-sense, single-stranded RNA genome with a length of approximately 15 kb. It encodes for a single polyprotein that is processed into several functional viral proteins including the structural proteins (e.g., N, M and E) and the non-structural proteins (e.g., Nsp1 to Nsp12). The genetic diversityof PRRSV strains is driven by mutations and recombination events, leading to the emergence of new variants and subtypes.Several key proteins play important roles in the replication, pathogenesis, and immune response to PRRSV.
The major envelope glycoprotein (GP5) is the most abundant protein found on the surface of PRRSV. It is involved in viral entry into host cells and is a major target for neutralizing antibodies. Other envelope proteins, including GP2, GP3, and GP4, also play important roles in viral entry and immune evasion.
The nucleocapsid protein is a structural protein that binds to the viral RNA to form the viral nucleocapsid. It plays a key role in viral replication and is also involved in the immune response to PRRSV.
The matrix protein is a structural protein that lines the inside of the viral envelope. It plays a role in virus assembly and release, and also interacts with the nucleocapsid protein.
The N protein, or nucleocapsid-associated protein, is another structural protein that binds to the viral RNA to form the nucleocapsid. It is also involved in the regulation of viral gene expression and the modulation of host immune responses.
The envelope glycoprotein (GP2) is a membrane-bound protein that is involved in viral assembly and release. It interacts with the matrix protein and other viral proteins to facilitate virus budding.
Non-structural proteins (NSPs) are proteins that are not part of the viral particle but are encoded by the virus and play important roles in viral replication and pathogenesis. NSP3, NSP11, and NSP12 are examples of PRRSV NSPs that have been extensively studied.
Ongoing research is focused on understanding the roles of these PRRSV proteins in viral pathogenesis and the development of effective treatments and vaccines for PRRSV infections in pigs.
The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.
Get the Latest News and Updates by Email
6393 Nancy Ridge Dr. Suite A
San Diego, CA 92121 USA
Fax: +1-858-909-0057
Get the Latest News and Updates by Email
© 2023 Bioclone Inc. All Rights Reserved.
Magnetic Beads Make Things Simple
